Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia

Autor: N. P. Kirsanova, O. V. Aleinikova, A. M. Kustanovich, T. V. Savitskay, R. I. Yutskevich, E. V. Volochnik, L. V. Baidun, Yu. E. Mareiko, Yu. S. Strongin, N. V. Minakovskay, N. V. Migal, I. V. Proleskovskay, I. V. Emelyanova, O. V. Karas, A. G. Drekov, M. M. Maschan, D. V. Litvinov, N. V. Myakova, E. V. Skorobogatova, D. D. Baidildina, I. I. Kalinina, G. G. Solopova, E. V. Suntsova, U. N. Petrova, L. A. Hachatryan, M. M. Scheider, A. A. Maschan
Jazyk: ruština
Rok vydání: 2022
Předmět:
Zdroj: Онкогематология, Vol 0, Iss 1, Pp 5-13 (2022)
Druh dokumentu: article
ISSN: 1818-8346
2413-4023
DOI: 10.17650/1818-8346-2009-0-1-5-13
Popis: Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with primary acute myeloid leukemia (AML) in Russia and Belarus are presented. 105 children at the age from 2 weeks till 18 years (a median age — 10.8 years) are included in the study. In 91 patients (86.7%) hematological remission have reached, from them 34 patients (37.4%) are in the first continuous complete remission (CCR). 6-years overall survival (OS), event-free survival (EFS) and relapse-free survival (RFS) rate for all group of patients was 0.35 ±} 0.05; 0.32 ±} 0.04 and 0.43 ±} 0.05, respectively. Survival analysis of children with different cytogenetic anomalies has allowed to define two prognostic groups of patients: the intermediate prognosis, including patients with normal kariotype and t(9;11) which EFS and RFS rate was 40—50%, and unfavorable prognosis with EFS and RFS rate less than 40%. The efficiency analysis of three postremission therapy type (allogeneic and autological hematopoietic stem cells transplantation (HSCT) and chemotherapy (HT)) in intermediate and unfavorable prognostis groups was carried out. High efficiency of related HLA-identical HSCT in patients both intermediate and unfavorable prognostis groups have been shown. Autological HSCT is possible in intermediate prognosis patients with absence of HLA-identical siblings and in unfavorable prognosis patients with absence of HLA-identical unrelated donor.
Databáze: Directory of Open Access Journals
Externí odkaz: